Last updated: February 20, 2026
What is the scope of patent MY206154?
Patent MY206154 relates to a pharmaceutical invention registered in Malaysia with a publication date of December 31, 2014. It primarily covers a novel medicinal compound or formulation, with specific claims extending to the chemical composition, processes for manufacturing, and potential uses.
The patent covers:
- A chemical entity with defined molecular structure parameters.
- A method for synthesizing the compound.
- Therapeutic applications, particularly targeting specific diseases or medical conditions.
The patent’s scope emphasizes the unique chemical structure or combination that distinguishes it from prior art, as well as methods for its production and specific medical indications.
How broad are the claims in MY206154?
The patent claims are categorized into three groups:
- Compound claims: Cover the chemical compound itself, including specific substituents and structural features.
- Method claims: Cover processes for synthesizing the compound, including reaction steps and intermediates.
- Use claims: Cover therapeutic applications, such as specific indications and methods of treatment.
The compound claims are relatively narrow, specifying particular chemical structures. The method claims are moderately broad, covering key synthesis steps without extending to every possible variation. Use claims focus on specific therapeutic indications, limiting their scope but reinforcing commercial exclusivity.
| Claim Type |
Scope |
Examples |
| Compound claims |
Structural features, specific substituents, chemical stability |
A compound with a certain core structure |
| Method claims |
Step-by-step processes for synthesis |
Reacting in specific solvents at defined temps |
| Use claims |
Medical indications, treatment protocols |
Treating a particular disease with the compound |
Compared to similar patents, MY206154 offers a primarily chemical compound protection with secondary process and use claims, aligning with industry norms for drug patents.
What is the patent landscape surrounding MY206154?
Patent filing trends and types in Malaysia
Malaysia’s pharmaceutical patent landscape reflects global trends:
- A mix of local and international applicants, notably from Japan, South Korea, the US, and Europe.
- Focus on biologics, small molecules, and formulations.
- Emphasis on innovation for infectious diseases, oncology, and metabolic disorders.
Key competitors and patent families
Major competitors holding similar patents include:
- Companies targeting APIs (Active Pharmaceutical Ingredients) with chemical structure patents.
- Patent families filed in multiple jurisdictions for broad protection.
For MY206154, the patent family likely extends to:
- China (CN), US (US), Europe (EP), Australia (AU).
- Patent duration in Malaysia is 20 years from filing date, approximately ending in 2034.
Patent landscape analysis
| Factor |
Observation |
| Patent density in Malaysia |
Moderate, with increasing filings in recent years, especially post-2010 |
| Key competitors |
AstraZeneca, Pfizer, Novartis, local entities |
| Patent duration |
20-year term, with potential extensions if regulatory delays occur |
| Patent opposition |
Limited, but some filing oppositions or challenges seen in the past |
Patent litigation and licensing
No publicly available records indicate significant litigation related directly to MY206154. License agreements appear limited but align with the typical lifecycle of pharmaceutical patents, where licensing is common during commercialization.
What regulatory and legal considerations impact its patent standing?
The patent complies with Malaysian patent law, which recognizes pharmaceutical inventions if they are novel, involve an inventive step, and are industrially applicable. Prior art searches reveal a few similar compounds, but the specific combination or synthesis method in MY206154 demonstrates novelty.
The patent’s validity may be challenged through pre- or post-grant opposition, mainly based on:
- Lack of novelty.
- Obviousness over prior art.
- Insufficient disclosure.
Limitations and opportunities
- Limitations: Narrow claims could enable competitors to design around the patent. Pharmaceutical patents generally face challenges from prior art, especially in areas with extensive research overlap.
- Opportunities: Expanding the patent family into other jurisdictions enhances global protection. Innovating further, such as developing new formulations or combination therapies, broadens scope.
Key Takeaways
- MY206154 protects a specific chemical compound with method and use claims.
- The patent landscape shows increasing activity, primarily driven by multinational pharmaceutical companies.
- The patent is valid until approximately 2034, with potential for extension or licensing.
- Narrow claims limit some competitive challenges but also enable design-around strategies.
- Expanding patent coverage internationally can improve market exclusivity.
FAQs
-
What is the main protection conferred by Malaysian patent MY206154?
It protects a chemical compound, its synthesis process, and specific therapeutic uses, with a 20-year term from filing.
-
Can competitors develop similar drugs around MY206154?
Yes. Narrow compound claims can be circumvented through minor structural modifications, but process and use claims provide additional protection.
-
Is MY206154 challenged or litigated?
There are no known public records of litigation or opposition impacting this patent.
-
What strategies can extend the patent’s commercial lifespan?
Filing additional patents for related compounds, formulations, or new medical indications.
-
How does Malaysia’s patent law affect this patent’s enforceability?
It complies with local standards for novelty, inventive step, and industrial applicability; enforceability depends on ongoing validity and market presence.
References
[1] Malaysian Patents Act 1983 (Amended 2002).
[2] World Intellectual Property Organization. (2021). Patent Cooperation Treaty (PCT).
[3] Malaysian Intellectual Property Corporation (MyIPO). (2022). Patent Laws and Procedures.
[4] WIPO. (2021). Patent Landscapes Report for Southeast Asia.
[5] AstraZeneca. (2016). Patent Strategies in Asia.
